Prognosis in patients with atrial fibrillation and CHA 2DS 2-VASc Score = 0 in a community-based cohort study

Journal of Cardiovascular Electrophysiology

Volumn 23, Issue 7, 2012, Pages 708-713

  Taillandier, Sophie ^a   Olesen, Jonas B ^b,c   Clémenty, Nicolas ^a   Lagrenade, Isabelle ^a   Babuty, Dominique ^a   Lip, Gregory Y H ^b   Fauchier, Laurent ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

antiplatelet agent; antithrombotic treatment; atrial fibrillation; bleeding; oral anticoagulation; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DIURETIC AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA ATHEROSCLEROSIS; ARTICLE; BLEEDING; BRUGADA SYNDROME; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CHA2DS2 VASC SCORE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COMMUNITY PROGRAM; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA BASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMORRHAGIC SHOCK; HUMAN; HYPERTENSION; INSTITUTIONAL CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY DISTRESS; RISK FACTOR; SIDE EFFECT; STROKE; SURVIVAL; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; FEMALE; FIBRINOLYTIC AGENTS; FRANCE; GUIDELINE ADHERENCE; HEART FAILURE; HEMORRHAGE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; STROKE; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861737050     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2011.02257.x     Document Type: Article

References (21)

1. Wolf PA, Abbott RD, Kannel WB,: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
2. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ,: Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
3. 2 score for stroke risk stratification in atrial fibrillation-Friend or foe? Thromb Haemost 2010; 104: 45-48.
4. Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T,: Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528-538.
5. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ,: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
6. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C,: Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ 2011; 342: d124.
7. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY,: A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011; 9: 39-48.
8. Lip GY, Frison L, Halperin JL, Lane DA,: Identifying patients at high risk for stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-2738.
9. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH,: Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology. Eur Heart J 2010; 31: 2369-2429.
10. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, Lõpez-Sendõn J, Vardas PE, Aliot E, Santini M, Crijns HJ,: Antithrombotic treatment in real-life atrial fibrillation patients: A report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026.
11. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P,: Bleeding risk assessment and management in atrial fibrillation patients: A position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011; 13: 723-746.
12. Gorin L, Fauchier L, Nonin E, Charbonnier B, Babuty D, Lip GY,: Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter. Implications of undertreatment and overtreatment in real life clinical practice: The Loire Valley Atrial Fibrillation Project. Chest 2011; 140: 911-917.
13. Lip GY, Frison L, Halperin JL, Lane DA,: Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 2011; 57: 173-180.
14. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Fukuyama T, Doi Y, Mochizuki S, Izumi T, Takekoshi N, Yoshida K, Hiramori K, Origasa H, Uchiyama S, Matsumoto M, Yamaguchi T, Hori M,: Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37: 447-451.
15. Hart RG, Pearce LA, Aguilar MI,: Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
16. Ogilvie IM, Welner SA, Cowell W, Lip GY,: Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. Thromb Haemost 2011; 106: 34-44.
17. Viles-Gonzalez JF, Fuster V, Halperin JL,: New anticoagulants for prevention of stroke in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22: 948-955.
18. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, RaunsÃ̧ J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C,: Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
19. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill SC, Shen WK, Gersh BJ,: Long-term progression and outcomes with aging in patients with lone atrial fibrillation: A 30-year follow-up study. Circulation 2007; 115: 3050-3056.
20. Poli D, Lip GY, Antonucci E, Grifoni E, Lane D,: Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol 2011; 22: 25-30.
21. Cha MJ, Oh GC, Hahn S, Choi EK, Oh S,: Thromboembolic risk evaluation in patients with atrial fibrillation using a modified CHADS(2) scoring system. J Cardiovasc Electrophysiol 2011; doi:.